REVIVA PHARMACEUTICALS HOLDINGS Business Summary

Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a clinical-stage biopharmaceutical company that operates on a pre-commercial business model, currently generating zero revenue as it advances its proprietary pipeline through the regulatory approval process. The company’s primary business segments are focused on the discovery and development of next-generation therapeutics for central nervous system (CNS), inflammatory, and cardiometabolic diseases. Its lead candidate, brilaroxazine (RP5063), is a multimodal neuromodulator that has completed a Phase 3 trial for schizophrenia and is slated to enter a second registrational Phase 3 trial (RECOVER-2) in the first half of 2026. Reviva competes directly with established and emerging players in the neuropsychiatric space, including Alkermes, Axsome Therapeutics, Vanda Pharmaceuticals, and Immunic, Inc. The company distinguishes itself by targeting a "superior safety" profile for brilaroxazine, specifically aiming to eliminate the metabolic and endocrine side effects common in existing antipsychotic treatments. Leadership is spearheaded by Founder, President, and CEO Dr. Laxminarayan Bhat, who established the company in 2006 and brings over 20 years of drug discovery expertise from roles at XenoPort and ARYx Therapeutics. Dr. Bhat, an inventor on over 100 patents and a former Alexander von Humboldt fellow, is supported by CFO Narayan Prabhu, a finance veteran with over two decades of experience, including a prior tenure as CFO of Sony Biotechnology. The company’s strategic direction is further guided by Independent Chairman Parag Saxena, a prominent private equity investor and co-founder of Vedanta Management who previously led high-profile investments in Amgen and Starbucks at INVESCO Private Capital. Notable institutional backing includes positions from Armistice Capital, Vanguard Group, and Geode Capital Management. As of March 8, 2026, the company is executing a 1-for-20 reverse stock split, effective March 9, to maintain its Nasdaq listing compliance.